TriangleFianlimab (NCT07188896)
Fianlimab trial for Advanced Renal Cell Carcinoma (aRCC) (NCT07188896). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic renal-cell cancer containing clear cells. No previous systemic kidney-cancer treatment is allowed, including before or after surgery. Measurable disease and tumor tissue are required.
The idea: compare immune-checkpoint combinations that release different brakes on T cells. Random assignment gives fianlimab plus cemiplimab, that pair plus ipilimumab, or ipilimumab plus nivolumab. All drugs are intravenous. Researchers measure confirmed tumor responses; doses and schedules are not published.
This phase 2 study plans 120 patients. Vanderbilt’s Brian Rini leads it; five US sites are recruiting, including Nashville.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.